Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
211-225 of 395
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
Project Oncology®Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Project Oncology®Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Charles Turck, PharmD, BCPS, BCCCP
Jonathon B. Cohen, MD, MS
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Project Oncology®Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Hallie Blevins, PhD
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Deep Breaths: Updates from CHESTEvolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Gerard A. Silvestri MD, MS, Master FCCP
Jessica S. Donington, MD, MSCR
Mariam Alexander, MD, PhD
Anurag Singh, MD
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Project Oncology®Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Ryan Quigley
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
Deep Breaths: Updates from CHESTOptimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
Gerard A. Silvestri MD, MS, Master FCCP
Jessica S. Donington, MD, MSCR
Mariam Alexander, MD, PhD
Anurag Singh, MD
- advertisement
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Project Oncology®Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Marlene Mimi Maeusli, PhD.
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
Project Oncology®Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
Paola Marignani, PhD, EMBA
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
Project Oncology®Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
John Cho, MD, PhD, FRCPC
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
Project Oncology®CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
Charles Turck, PharmD, BCPS, BCCCP
Samuel Yamshon, MD
Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer
Project Oncology®Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer
Paola Marignani, PhD, EMBA
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
Project Oncology®The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
John Cho, MD, PhD, FRCPC
- advertisement
From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care
Project Oncology®From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care
Ryan Quigley
Clinical Outcomes of Radiation vs. Chemoradiation in Recurrent Endometrial Cancer
Advances in Women's HealthClinical Outcomes of Radiation vs. Chemoradiation in Recurrent Endometrial Cancer
Ann Klopp, M.D., Ph.D.
Optimizing Outcomes in Endometrial Cancer: From Surgery to Recurrence Management
Advances in Women's HealthOptimizing Outcomes in Endometrial Cancer: From Surgery to Recurrence Management
Ann Klopp, M.D., Ph.D.
